Assignment history

Inventors

• Nikolaj Skak
• Per Holm

No unusual patterns observed regarding inventor departures.

Original assignee

Veloxis Pharmaceuticals AS.
Veloxis Pharmaceuticals is a pharmaceutical company that develops and commercializes immunosuppressive therapeutics for organ transplant recipients. Their primary product, Envarsus XR (tacrolimus extended-release tablets), embodies the claims of US10166190B2. Veloxis Pharmaceuticals AS was acquired by Asahi Kasei in February 2021. As of today, Veloxis Pharmaceuticals Inc. (the current assignee) appears to be an operating subsidiary of Asahi Kasei Pharma.

Assignment timeline

• 2018-02-15 (executed) / recorded 2018-02-23 — Reel 044030/0858

  • Conveyance: Security Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
  • Correspondent: Ropes & Gray LLP, 1211 Avenue of the Americas, New York, NY 10036.
  • Context: Securitization (granting a security interest in patents as collateral for a loan)

• 2020-01-23 (executed) / recorded 2020-02-04 — Reel 048705/0137

  • Conveyance: Release by Secured Party
  • Assignor: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
  • Assignee: VELOXIS PHARMACEUTICALS A/S
  • Correspondent: Ropes & Gray LLP, 1211 Avenue of the Americas, New York, NY 10036. This correspondent also appears on reel 044030/0858.
  • Context: Release of security interest

• 2021-03-17 (executed) / recorded 2021-03-24 — Reel 051939/0751

  • Conveyance: Assignment of Assignors Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: Potter Minton, P.C., P.O. BOX 359, TYLER, TX 75710.
  • Context: Internal reorganization / transfer between related entities

• 2021-04-02 (executed) / recorded 2021-04-05 — Reel 051994/0270

  • Conveyance: Assignment of Assignors Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: Potter Minton, P.C., P.O. BOX 359, TYLER, TX 75710. This correspondent also appears on reel 051939/0751.
  • Context: Internal reorganization / transfer between related entities (likely a confirmatory assignment or correction)

• 2024-06-07 (executed) / recorded 2024-06-13 — Reel 063678/0784

  • Conveyance: Change of Address
  • Assignor: VELOXIS PHARMACEUTICALS INC.
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: Cantor Colburn LLP, 20 Church St 22nd Floor, Hartford, CT 06103.
  • Context: Change of address only

Timeline diagram

timeline
    title Ownership of US 10166190
    2017 : Filed
    2018 : Security interest to Athyrium
    2019 : Issued
    2020 : Security interest released
    2021 : Assigned to Veloxis Inc
         : Confirmatory assignment
    2024 : Change of address

NPE / troll-pattern signals

1. Shell-entity transfer — not present. All recorded assignees (Veloxis Pharmaceuticals A/S, Athyrium Opportunities III Acquisition LP, and Veloxis Pharmaceuticals Inc.) appear to be legitimate operating companies or financial entities, not shell corporations. Veloxis Pharmaceuticals is a commercial entity. Athyrium is a healthcare-focused investment firm.
2. Known asserter in the chain — not present. None of the listed assignees or assignors (Veloxis Pharmaceuticals A/S, Athyrium Opportunities III Acquisition LP, Veloxis Pharmaceuticals Inc.) are identified as known NPEs or patent asserters.
3. Repeat correspondent across the chain — present. Ropes & Gray LLP appears on reel 044030/0858 and reel 048705/0137. Potter Minton, P.C. appears on reel 051939/0751 and reel 051994/0270. While these are repeat correspondents, the transfers appear to be related to financing and internal corporate restructuring, which are common for operating companies.
4. Cascading transfers — not present. The assignments are spread out over several years, and the transfers between Veloxis A/S and Veloxis Inc. appear to be internal corporate restructuring, not rapid transfers through multiple shell entities.
5. Pre-litigation transfer — unclear. While there are ongoing litigations for this patent, the assignment records do not show a clear transfer within 6 months before the first litigation filing. The earliest litigation noted on Google Patents is for 2022-07-05, while the transfers to Veloxis Pharmaceuticals Inc. happened in March and April 2021.
6. Bankruptcy fire-sale — not present. There is no indication that Veloxis Pharmaceuticals A/S or Veloxis Pharmaceuticals Inc. have undergone bankruptcy proceedings leading to a patent sale.
7. Privateering — not present. No evidence suggests that Veloxis Pharmaceuticals has transferred the patent to an NPE to assert on their behalf.
8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at any known defensive aggregator.

Verdict

Operating-company assertion
The current assignee, Veloxis Pharmaceuticals Inc., is an operating pharmaceutical company that sells products embodying the claims of the patent. The assignment history reflects internal corporate restructuring and a security interest, typical for operating businesses, rather than NPE-driven transfers. There are ongoing litigations related to this patent, suggesting an operating company asserting its intellectual property.

USPTO Assignment Center search for US10166190: https://assignmentcenter.uspto.gov/